The MPCT-012L clinical research study is for people who have Aggressive B-cell non-Hodgkin Lymphoma (NHL). The study will test a new investigational treatment to learn if it can be used for people with aggressive B-cell non-Hodgkin Lymphoma (NHL).
People may be able to join the study if they meet the following requirements*:
18 years or older
Able to undergo the required study procedures
A diagnosis of Aggressive B-cell non-Hodgkin Lymphoma (NHL):
*Other study requirements will apply
Participation in the MPCT-012L study lasts about 2 years. Study participants can expect the following:
Participation in a clinical study is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.
IMPT-314 is a type of T-Cell therapy. To create IMPT-314, some of your own white blood cells will be collected and modified so that they can identify cancer cells. Then, the IMPT-314 cells will be given back to you to potentially kill the cancer cells.
IMPT-314 is investigational, which means it can only be used in research studies. It has not been approved by the United States Food and Drug Administration (FDA) as a therapy for Aggressive B-cell non-Hodgkin Lymphoma (NHL).
Yes, as a participant in the MPCT-012L study, you will receive active study treatment.
Investigational means the study treatment is not approved by regulatory authorities like the US Food and Drug Administration (FDA), and it can only be used in clinical research studies like MPCT-012L.
Aggressive B-cell non-Hodgkin Lymphoma is a type of cancer that begins in your lymphatic system, which is part of the body's germ-fighting immune system, and spreads very quickly in your body.
*Other forms of Aggressive B-cell non-Hodgkin Lymphoma (NHL) may also qualify for eligibility in the study.
Where can I learn more?
Cleveland Clinic
Lymphoma Research Foundation
National Library of Medicine
Lymphoma Action
Here are some common questions and answers about study participation.
Clinical research studies, or trials, help scientists and doctors explore whether a medical strategy, device, or medication is safe and effective for people. Before any medication can be approved and made available to the public, it must go through several phases of clinical research.
Before enrolling in a clinical trial, you must sign an Informed Consent Form (ICF). The ICF contains information about the study, including study goals, how long the study will last, benefits and risks, and the tests and procedures you will receive.
Study participation usually involves visiting a clinic regularly, taking or receiving an investigational medicine, and having assessments to monitor your health. You can still see your regular doctor, but you should let them know that you are participating in a study.
Participation in clinical research studies is your choice, and you may stop at any time.
If you have additional questions about participating in a clinical research study, visit clinicaltrials.gov to see a full list of participating sites.
Travel support may be available, if needed. To see a full list of all participating sites in the trial please visit clinicaltrials.gov.